SEC Form 4 · accession 0001485003-18-000045
Sesen Bio, Inc. · SESN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard F Fitzgerald
Officer — Chief Financial Officer
Period of report
Apr 9, 2018
Accepted (ET)
Apr 11, 2018 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001485003
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $1.50 | Apr 9, 2018 | A | 200,000 | A | — | Apr 8, 2028 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1On April 9, 2018, the reporting person was awarded options to purchase 200,000 shares of common stock of Eleven Biotherapeutics, Inc. (the "Company"), which options vest 6.25% every three months over four years, provided the reporting person is employed by the Company on each such vesting date.